Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial.
Detecting early cancer signals in blood doesn't guarantee this particular drug helps, showing the need to test what actually works for molecular residual disease.
The ALTAIR phase 3 RCT tested whether treating ctDNA-positive colorectal cancer patients (molecular residual disease, no imaging evidence of recurrence) with FTD/TPI versus placebo improves disease-free survival. Despite a numeric trend favoring FTD/TPI, the trial did not reach statistical significance, providing important evidence that this ctDNA-guided strategy does not clearly benefit patients in this setting with the chosen agent.
What the study was
- Study design
- Randomized double-blind phase 3 trial (ALTAIR, embedded in CIRCULATE-Japan platform)
- Population
- Adults with resected stage 0-IV colorectal cancer who became ctDNA-positive after completion of standard-of-care therapy with no radiological evidence of disease
- Sample size
- 243
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Nature Medicine
Why it surfaced
Phase 3 RCT in Nature Medicine definitively addressing ctDNA-guided post-adjuvant therapy in colorectal cancer. The negative result (primary endpoint not met) is high-value pipeline intelligence — it constrains the ctDNA-to-treatment paradigm and informs future trial design in this space. Phase 3 design and Nat Med publication warrant HIGH classification despite negative outcome.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.